NeuroPace, Inc.
NASDAQ:NPCEMedical - Devices
Healthcare
$8.14 +0.30%
+$0.05 today
- Market cap
- $280.44M
- Beta
- 1.88
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.64
52W Low $7.56High $19.60
Volume 0.35M
Average 0.18M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$11.01M
FY 2025 · Annual
Investing Cash Flow
-$332,000.00
FY 2025 · Annual
Financing Cash Flow
$19.60M
FY 2025 · Annual
+353.0% YoYCash Flow Statement
USD
Metric | FY 2021 Dec 2021 | FY 2022 Dec 2022 | FY 2023 Dec 2023 | FY 2024 Dec 2024 | FY 2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.08M) | (47.08M) | (32.96M) | (27.14M) | (21.47M) |
| Depreciation & Amortization | 296K | 2.99M | 1.61M | 1.77M | 1.95M |
| Deferred Income Tax | 5.48M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.29M | 8.35M | 9.56M | 10.28M | 11.09M |
| Change in Working Capital | 368K | (4.79M) | (2.48M) | (5.45M) | (4.01M) |
| Accounts Receivables | 1.3M | (391K) | (4.85M) | (537K) | (1.83M) |
| Inventory | (1.16M) | (2.13M) | (1.7M) | 251K | (3.67M) |
| Accounts Payables | 479K | 647K | 240K | 671K | (730K) |
| Other Working Capital | (259K) | (2.91M) | 3.82M | (5.84M) | 2.22M |
| Other Non-Cash Items | 1.07M | 3.67M | 4.58M | 2.59M | 1.43M |
| Operating Cash Flow | (24.58M) | (36.87M) | (19.7M) | (17.95M) | (11.01M) |
| Capital Expenditures | (384K) | (603K) | (173K) | (306K) | (332K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (85.01M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 24.4M | 23.2M | 9.3M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (85.4M) | 23.8M | 23.03M | 8.99M | (332K) |
| Debt Repayment | (4.09M) | 0 | 0 | 0 | (2.07M) |
| Common Stock Issued | 109.09M | 0 | 7.89M | 3.28M | 71.76M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (49.55M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.47M) | 490K | 239K | 1.05M | (543K) |
| Financing Cash Flow | 102.53M | 490K | 8.13M | 4.33M | 19.6M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (7.45M) | (12.58M) | 11.45M | (4.63M) | 8.26M |
| Free Cash Flow | (24.96M) | (37.47M) | (19.87M) | (18.26M) | (11.34M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$21.5M
+ D&A$1.9M
+ Stock-Based Comp$11.1M
+ Deferred Tax$0
- Working Capital-$4.0M
+ Other Non-Cash$1.4M
= Operating Cash Flow-$11.0M
- Capex-$332.0K
= Free Cash Flow-$11.3M
Analysis
FY2025 free cash flow is -$11.3M. FCF conversion is 52.8% of net income. Operating cash flow was -$11.0M, with capex of -$332.0K. The largest bridge item is Stock-Based Comp at $11.1M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 21, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 |
Does NPCE generate free cash flow?
NeuroPace, Inc. (NPCE) generated -$11.34M of free cash flow in fiscal 2025.
How much operating cash flow does NPCE produce?
Operating cash flow was -$11.01M, before capital expenditures of $332,000.00.
Continue the stock analysis
Jump to another research area for this company.